Rep. Gottheimer Urges Speedy FDA Action on Experimental Gilead COVID-19 Treatment, Urges Gilead to Continue Emergency Access to Patients With Severe Symptoms
March 24, 2020
March 24, 2020
WASHINGTON, March 24 -- Rep. Josh Gottheimer, D-New Jersey, issued the following statement:
"Right now, Gilead Sciences has halted emergency individual 'compassionate use' access to its experimental COVID-19 drug remdesivir, citing overwhelming demand, as the company works to expand access programs.
"While compassionate use requests may still be made for pregnant women and children under 18 years of age with confirmed COVID-19 and severe manifestations of dis . . .
"Right now, Gilead Sciences has halted emergency individual 'compassionate use' access to its experimental COVID-19 drug remdesivir, citing overwhelming demand, as the company works to expand access programs.
"While compassionate use requests may still be made for pregnant women and children under 18 years of age with confirmed COVID-19 and severe manifestations of dis . . .